Literature DB >> 9075477

Human submandibular saliva specifically inhibits HIV type 1.

T Nagashunmugam1, H M Friedman, C Davis, S Kennedy, L T Goldstein, D Malamud.   

Abstract

Studies from a number of laboratories have shown the presence of factor(s) in whole, parotid, and submandibular human saliva capable of inhibiting HIV-1 infectivity in vitro. Data from our laboratory suggested that the level of anti-HIV-1 activity is higher in submandibular than parotid or whole saliva. Previous results obtained with pooled submandibular saliva from seronegative individuals included a filtration step following saliva-virus interaction. In this article, we present data on the HIV-1 inhibitory activity of individual submandibular saliva samples collected from 15 donors. We show that although anti-HIV activity is quantitatively similar in most individuals (9 of 15), some (4 of 15) are much less active than others and some (2 of 15) lack inhibitory activity. We also show that for most individuals the level of anti-HIV inhibitor is similar with or without a filtration step. However, 2 of the 15 samples demonstrated activity only after filtration. The quantitative and qualitative anti-HIV activity of individual saliva samples appeared to reflect differences in the individual donors. We further show that the anti-HIV activity of submandibular saliva is demonstrated not only against laboratory strains of HIV-1 but is similarly active against three clinical HIV-1 isolates. In contrast, submandibular saliva had little effect on the infectivity of HIV-2 or SIV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9075477     DOI: 10.1089/aid.1997.13.371

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Authors:  Jessica S Thomas; Nedra Lacour; Pamela A Kozlowski; Steve Nelson; Gregory J Bagby; Angela M Amedee
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

2.  The recombinant N-terminal region of human salivary mucin MG2 (MUC7) contains a binding domain for oral Streptococci and exhibits candidacidal activity.

Authors:  B Liu; S A Rayment; C Gyurko; F G Oppenheim; G D Offner; R F Troxler
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

3.  Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids.

Authors:  Shamim H Kazmi; Julian R Naglik; Simon P Sweet; Robert W Evans; Siobhan O'Shea; Jangu E Banatvala; Stephen J Challacombe
Journal:  Clin Vaccine Immunol       Date:  2006-08-23

4.  Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.

Authors:  Habtom H Habte; Corena de Beer; Zoë E Lotz; Paul Roux; Anwar S Mall
Journal:  Virol J       Date:  2010-10-14       Impact factor: 4.099

Review 5.  The mouth: a gateway or a trap for HIV?

Authors:  Daniel Malamud; Sharon M Wahl
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

Review 6.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  HIV envelope binding by macrophage-expressed gp340 promotes HIV-1 infection.

Authors:  Georgetta Cannon; Yanjie Yi; Houping Ni; Earl Stoddard; David A Scales; Donald I Van Ryk; Irwin Chaiken; Daniel Malamud; Drew Weissman
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

8.  gp340 promotes transcytosis of human immunodeficiency virus type 1 in genital tract-derived cell lines and primary endocervical tissue.

Authors:  Earl Stoddard; Houping Ni; Georgetta Cannon; Chunhui Zhou; Neville Kallenbach; Daniel Malamud; Drew Weissman
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

Review 9.  Selective transmission of R5 HIV-1 variants: where is the gatekeeper?

Authors:  Jean-Charles Grivel; Robin J Shattock; Leonid B Margolis
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

10.  The role of crude saliva and purified salivary mucins in the inhibition of the Human Immunodeficiency Virus type 1.

Authors:  Julia Peacocke; Zoe Lotz; Corena de Beer; Paul Roux; Anwar S Mall
Journal:  Virol J       Date:  2012-08-28       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.